Tahoe Therapeutics

Name: Tahoe Therapeutics
Brand: Tahoe Therapeutics

AI Native

Mapping how chemistry perturbs biology to build a virtual model of the human cell. Formerly known as Vevo Therapeutics.

Est 2022|Valuation $131M|Raised $50M

LinkedIn 9K|Website|Web traffic 3K|FTEs 38

MarketsData Science & Machine Learning Platforms

01Competitive Landscape

Narrative analysis

Differentiation: Tahoe emphasizes perturbation-first single-cell datasets and publishes open models and related code to support research evaluation.
Competitor strengths: Recursion and Schrödinger provide alternative vendor profiles with more established enterprise track records (in their respective domains), documented partnerships, and more conventional procurement options.
Pricing comparison: Many vendors in adjacent categories use negotiated pricing for enterprise engagements; open assets may be available from some providers but enterprise services are typically commercial.
Market adoption trends: Tahoe has visible engagement in open-science activities (dataset downloads, public code, community events). Competing organizations show traction through enterprise partnerships and, in some cases, public-company disclosures.

- Differentiation: Tahoe emphasizes perturbation-first single-cell datasets and publishes open models and related code to support research evaluation. - Competitor strengths: Recursion and Schrödinger provide alternative vendor profiles with more established enterprise track records (in their respective domains), documented partnerships, and more conventional procurement options. - Pricing comparison: Many vendors in adjacent categories use negotiated pricing for enterprise engagements; open assets may be available from some providers but enterprise services are typically commercial. - Market adoption trends: Tahoe has visible engagement in open-science activities (dataset downloads, public code, community events). Competing organizations show traction through enterprise partnerships and, in some cases, public-company disclosures.

	Tahoe Therapeutics	Recursion Pharmaceuticals	Schrödinger
Starting Price	Not publicly listed (commercial engagements are negotiated; open datasets are available)	Not publicly listed (partnership-driven)	Not publicly listed for core platform (enterprise licensing); some education/training pricing is public
Typical Use Case	Perturbation-focused single-cell datasets and foundation models for research and discovery	Industrialized cellular phenotyping and large-scale partnerships	Physics/chemistry-based modeling for small-molecule discovery and enterprise workflows
Key Strength	Large perturbation-focused single-cell dataset releases and open-model artifacts	Documented partnerships and operational experience at scale	Mature enterprise adoption in computational chemistry and formal licensing processes
Key Weakness	Limited publicly documented translational outcomes and limited enterprise security/compliance documentation	Not focused on single-cell perturbation-first modeling	Not designed specifically for cell-state perturbation modeling